Categories: EHRNewsPharmaceutical

Keros Therapeutics to Present at the SVB Securities Global Biopharma Conference

LEXINGTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 3:40 p.m. Eastern time.

A live audio webcast of the fireside chat presentation will be available at https://wsw.com/webcast/svb8/kros/1640061 and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.

About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of a number of tissues, including blood vessels and heart tissue. Keros’ lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ lead small molecule product candidate, KER-047, is being developed for the treatment of functional iron deficiency. Keros’ third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders.

Investor Contact:
Justin Frantz
jfrantz@soleburystrat.com        
617-221-9100

Staff

Recent Posts

Corti Unlocks “Surgical” AI Improvement, Outperforming Big Tech in Interpretability Benchmark

New "GIM" method tops MIB global leaderboard, offering the industry a scalable way to inspect…

4 hours ago

New Year’s Fitness Resolutions: Why Recovery Is the Missing Piece

HOTWORX Shares Expert Guidance on Building Sustainable Fitness Goals That Go Beyond Just Working OutNEW…

4 hours ago

Zoom Room Dog Training Partners with Fi to Bring Dog Fitness Tracking Nationwide

Leading Dog Training Franchise Expands Human Level Fitness Tracking to Select LocationsLOS ANGELES, Dec. 18,…

4 hours ago

Top CEOs, Physicians and Innovators: HIMSS26 Announces Speakers and Exclusive Executive Experience Line-up

AdventHealth's David Banks, Savannah Bananas' Tyler Gillum, AMA's John Whyte, MD, MPH and Lenox Hill…

4 hours ago

WebPT Announces Advocate Physical Therapy and Tilton’s Therapy as Winners of the 2025 Ascend Awards

Practice of the Year and Innovator of the Year honorees recognized for patient-centered care, operational…

4 hours ago

Hootan Troy Farahmand: Leading With Purpose and Compassion in Modern Healthcare

As Chief Executive Officer of Alexso, Inc., a nationwide pharmaceutical distributor, Farahmand has earned recognition…

4 hours ago